M1 Positive Allosteric Modulator ML169

M1@ Alzheimer Chemotherapy

Abstract

 

 

 

The M₁ muscarinic acetylcholine receptor is thought to play an important role in memory and cognition, making it a potential target for the treatment of Alzheimer’s disease (AD) and schizophrenia.

 

 

Moreover, M₁ interacts with BACE1 and regulates its proteosomal degradation, suggesting selective M₁ activation could afford both palliative cognitive benefit as well as disease modification in AD. A key challenge in targeting the muscarinic acetylcholine receptors is achieving mAChR subtype selectivity.

 

 

Our lab has previously reported the M₁ selective positive allosteric modulator ML169. Herein we describe our efforts to further optimize this lead compound by preparing analogue libraries and probing novel scaffolds. We were able to identify several analogues that possessed submicromolar potency, with our best example displaying an EC₅₀ of 310 nM.

 

 

The new compounds maintained complete selectivity for the M₁ receptor over the other subtypes (M₂–M₅), displayed improved DMPK profiles, and potentiated the carbachol (CCh)-induced excitation in striatal MSNs. Selected analogues were able to potentiate CCh-mediated nonamyloidogenic APPsα release, further strengthening the concept that M₁ PAMs may afford a disease-modifying role in the treatment of AD.

 

Keywords:

Muscarinic; acetylcholine; positive allosteric modulator (PAM); ML169; Alzheimer’s disease (AD); medium spiny neurons (MSNs); MLPCN

View: ACS ActiveView PDF | PDF | PDF w/ Links | Full Text HTML

Citing Articles

View all 8 citing articles
Citation data is made available by participants in CrossRef's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search in SciFinder.
This article has been cited by 4 ACS Journal articles (4 most recent appear below).

• 

  M4 mAChR-Mediated Modulation of Glutamatergic Transmission at Corticostriatal Synapses

  Tristano Pancani, Caroline Bolarinwa, Yoland Smith, Craig W. Lindsley, P. Jeffrey Conn, and Zixiu Xiang
  ACS Chemical Neuroscience2014 5 (4), 318-324

  • M4 mAChR-Mediated Modulation of Glutamatergic Transmission at Corticostriatal Synapses

    TristanoPancani, CarolineBolarinwa, YolandSmith, Craig W.Lindsley, P. JeffreyConn, and ZixiuXiang
    ACS Chemical Neuroscience2014 5 (4), 318-324
    The striatum is the main input station of the basal ganglia and is extensively involved in the modulation of motivated behavior. The information conveyed to this subcortical structure through glutamatergic projections from the cerebral cortex and thalamus ...
    
    Abstract | Full Text HTML | PDF | PDF w/ Links
• 

  Discovery of the First M₅-Selective and CNS Penetrant Negative Allosteric Modulator (NAM) of a Muscarinic Acetylcholine Receptor: (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)

  Patrick R. Gentry, Masaya Kokubo, Thomas M. Bridges, Nathan R. Kett, Joel M. Harp, Hyekyung P. Cho, Emery Smith, Peter Chase, Peter S. Hodder, Colleen M. Niswender, J. Scott Daniels, P. Jeffrey Conn, Michael R. Wood, and Craig W. Lindsley
  Journal of Medicinal Chemistry2013 56 (22), 9351-9355

  • Discovery of the First M₅-Selective and CNS Penetrant Negative Allosteric Modulator (NAM) of a Muscarinic Acetylcholine Receptor: (S)-9b-(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)

    Patrick R.Gentry, MasayaKokubo, Thomas M.Bridges, Nathan R.Kett, Joel M.Harp, Hyekyung P.Cho, EmerySmith, PeterChase, Peter S.Hodder, Colleen M.Niswender, J. ScottDaniels, P. JeffreyConn, Michael R.Wood, and Craig W.Lindsley
    Journal of Medicinal Chemistry2013 56 (22), 9351-9355
    A functional high throughput screen and subsequent multidimensional, iterative parallel synthesis effort identified the first muscarinic acetylcholine receptor (mAChR) negative allosteric modulator (NAM) selective for the M5 subtype. ML375 is a highly ...
    
    Abstract | Full Text HTML | PDF | PDF w/ Links
• 

  Development of M₁ mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits

  Briana J. Davie, Arthur Christopoulos, and Peter J. Scammells
  ACS Chemical Neuroscience2013 4 (7), 1026-1048

  • Development of M₁ mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits

    Briana J.Davie, ArthurChristopoulos, and Peter J.Scammells
    ACS Chemical Neuroscience2013 4 (7), 1026-1048
    Since the cholinergic hypothesis of memory dysfunction was first reported, extensive research efforts have focused on elucidating the mechanisms by which this intricate system contributes to the regulation of processes such as learning, memory, and higher ...
    
    Abstract | Full Text HTML | PDF | PDF w/ Links
• 

  Discovery of Novel N-Substituted Oxindoles as Selective M₁ and M₄ Muscarinic Acetylcholine Receptors Partial Agonists

  Takaaki Sumiyoshi, Takeshi Enomoto, Kentaro Takai, Yoko Takahashi, Yasuko Konishi, Yoshiharu Uruno, Kengo Tojo, Atsushi Suwa, Harumi Matsuda, Tomokazu Nakako, Mutsuko Sakai, Atsushi Kitamura, Yasuaki Uematsu, and Akihiko Kiyoshi
  ACS Medicinal Chemistry Letters2013 4 (2), 244-248

  • Discovery of Novel N-Substituted Oxindoles as Selective M₁ and M₄ Muscarinic Acetylcholine Receptors Partial Agonists

    TakaakiSumiyoshi, TakeshiEnomoto, KentaroTakai, YokoTakahashi, YasukoKonishi, YoshiharuUruno, KengoTojo, AtsushiSuwa, HarumiMatsuda, TomokazuNakako, MutsukoSakai, AtsushiKitamura, YasuakiUematsu, and AkihikoKiyoshi
    ACS Medicinal Chemistry Letters2013 4 (2), 244-248
    Activation of the M1 and M4 muscarinic acetylcholine receptors is thought to play an important role in improving the symptoms of